Daily News & Analysis
  • Home
  • Mumbai
  • India
  • World
  • Money
  • Sport
  • Entertainment
  • Opinion
  • Speak Up
  • Health
  • Lifestyle
  • Sci/Tech
  • Academy
  • Gallery
  • Blogs
  • E-Paper
Sunday, November 22, 2009

Columns

Advanced Search

Pillman
Syndicate
this column

What makes Genentech so special is its innovation culture

Compelling as it was, reacquisition of the company shows Roche’s management bandwidth & far sight, too.
March 19, 2009

Will affordable drugs remain a need unfulfilled?

Making drugs affordable and accessible to the needy masses has been the stated intention of the UPA government from the time it came to power five years ago.
February 26, 2009

Clinical trials for multinationals ‘killing the poor in India’

Close on heels of the controversy about an alleged clinical trial death on one of Wyeth’s paediatric vaccines, there is more damning revelation
February 19, 2009

Sanofi fits better with Piramal than Glaxo

After Pfizer declared its plans to acquire Wyeth that will swell its topline to $70 billion, the most obvious question was when Pfizer’s peers will react to these moves.
February 9, 2009

Foreign drug majors’ latest gambit — restraining the Drug Controller

Patent-related rows between Indian and multinational drug companies are here to stay. If anything, the fight between the two lobbies will get fiercer by the day.
January 15, 2009

FCCBs prove a nagging headache for domestic pharma companies

What was perceived to be an easy option to raise funds through foreign currency convertible bonds (FCCBs) two to three years ago is turning out to be a nightmare for Indian drug makers.
January 9, 2009

Odds heavy against Wockhardt finding a way out

As we get acclimatised to the unprecedented global economic calamity, leading Indian drug companies are taking it on their chins. One such big name is Wockhardt.
December 25, 2008

Seismic shifts in pharma spell dooms for firms

Seismic shifts in pharmaceutical industry spells doom for firms both big and small.
December 18, 2008

Pharma Inc must come clear on clinical trials

Pharma Inc must come clear on clinical trials, build confidence. Recent reports of infant deaths due to faulty trials make a compelling case for this
December 11, 2008

European Commission exposé has pharma innovators in a bind

Some of the dirtiest tricks of global drug giants to corner market share and maintain monopoly have been thrown in the open by a 426-page preliminary report of the European Commission.
December 4, 2008

Good traction in Indian pharmaceuticals research

In a move that stunned many industry watchers, Pfizer announced its plans to withdraw from further research on heart drugs.
October 9, 2008

The only ‘consolidator’ in world generics has guns blazing

Teva never fails to amaze. Barely a month after it struck a deal to own the US-based Barr Labs for nearly $8 billion, the company recently did one more unique collaboration
October 2, 2008

Did Ranbaxy deserve the blow BY US FDA?

Pharma major may have erred in not taking timely remedial action.
September 25, 2008
«
1
2
3
4
»


Reports
  • Big Pharma must mend its ways to succeed in India
  • Indian pharma faces the big-league challenge
  • Flu: Place public health above corporate interest
  • For local pharma, move to next level will take concerted play
  • Merck’s Schering-Plough buy is a win-win deal

Our columnists
  • Anil Dharker
  • Antara Dev Sen
  • Arati R Jerath
  • Arati R. Jerath
  • Ayaz Memon
  • Cyrus Broacha
  • Dilip Vengsarkar
  • Gaurav Kapur
  • Javed Gaya
  • Madhu Jain
  • Magandeep Singh
  • Malavika Sangghvi
  • Mallika Sarabhai
  • Meghnad Desai
  • N Raghuraman
  • Parsa Venkateshwar Rao Jr
  • R Jagannathan
  • Ranjona Banerji
  • Robin Sharma
  • Sandeep Shanbhag
  • Sathya Saran
  • Siddharth Bhatia
  • Sidharth Bhatia
  • Suresh Nair
  • Venkatesan Vembu
  • Vinay Kamat
Contributors
  • Ankita Pandey
  • Arjun Parthasarathy
  • B Krishnakumar
  • Deblina Chakrabarty
  • Fahad K Samaar
  • Firoz Bakht Ahmed
  • Koel Purie
  • Manjula Pooja Shroff
  • MS Kamath
  • Mukul G Asher
  • Naini Setalvad
  • Prof R Vaidyanathan
  • R N Bhaskar
  • Rakesh Bhatnagar
  • S Gangadharan
  • Shraddha Jahagirdar Saxena
  • Sumit Chakraberty
  • Vijay L Bhambwani
  • Vivek Kaul
  • Yatin Pandya
  • Zaheer Abbas
Popular Columns »
  • Suresh Nair : 2012: The end?
  • R Jagannathan: Fighting Hindi hegemony
  • Anil Dharker : For Muslims, the enemy lies within
  • Ayaz Memon: Twenty years is a couple of lifetimes in any sport
  • Mallika Sarabhai: Dubai: City of gold
  • Venkatesan Vembu: Before his Asia trip Obama should see 2012
  • Ranjona Banerji : Maharashtra’s issues come home to roost
  • Sandeep Shanbhag : Go for gold — the ETF way
  • R Jagannathan: Pink Panther strikes
  • Sidharth Bhatia : Laurel & Hardy are passé
About us | Contact us | Advertise with us | Subscription | Reprint rights
© 2005-2009 Diligent Media Corporation Ltd. All rights reserved.